Priavoid uses image phage display selection and various optimization technologies to develop all-D-peptides, compounds composed exclusively of D-enantiomeric (mirror image) amino acids. In contrast to natural peptides consisting of L-amino acids, all-D-peptides are resistant to proteases and are degraded very slowly. Therefore, they can be administered orally, for example as a tablet.

Pre-clinical and clinical trials are pursued at Priavoid for the development of drugs for treatment of neurodegenerative diseases.


The drug pipeline of Priavoid is composed of 6 compounds in development with 5 CNS diseases

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!



To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice